Shareholders Approve Veraxa Biotech Merger Amidst 99.67% Share Redemptions

summarizeSummary

Voyager Acquisition Corp. shareholders approved the business combination with Veraxa Biotech AG, but 99.67% of Class A shares were redeemed, leaving minimal funds in the trust account.

check_boxKey Events

• Business Combination Approved

  Shareholders formally approved the Business Combination Agreement with Veraxa Biotech AG, allowing the merger to proceed. This follows news of approval on March 13, 2026.

• High Share Redemptions

  An aggregate of 25,217,315 Class A ordinary shares, representing approximately 99.67% of outstanding shares, were redeemed. This confirms the high redemption rate reported in news on March 11, 2026.

• Minimal Trust Funds Remaining

  Following redemptions, only approximately $885,556 will remain in the SPAC's trust account, significantly reducing the capital available for the combined entity.

• Governance Provisions Approved

  Shareholders also approved the Initial Merger and several non-binding advisory proposals related to PubCo's charter, including authorized share capital and director removal provisions.

auto_awesomeAnalysis

This 8-K formally confirms the shareholder approval of the business combination with Veraxa Biotech AG, a critical step for the SPAC to complete its merger. However, the overwhelming 99.67% redemption rate of Class A ordinary shares is a significant negative, indicating that nearly all capital from the SPAC's trust account has been withdrawn. This leaves only approximately $885,556 in the trust, severely limiting the capital contribution from the SPAC to the combined entity. While the merger proceeds, the high redemptions suggest a lack of investor confidence in the SPAC's original structure or the proposed deal, and will likely impact the post-merger company's financial flexibility.